Industry partnerships

An important part of EMBL-EBI’s mission is to disseminate cutting-edge technologies to industry. Some 20% of our users are engaged in industrial R&D and our services are constantly evolving to reflect the rapidly changing needs of this crucial sector.

As biology becomes more data-driven, the bioindustries are forming pre-competitive collaborations, as well as open-source software and informatics standards to improve efficiency and reduce costs. These are the core elements of our Industry Programme, a forum for interaction and knowledge exchange for those employed at the forefront of industrial bioinformatics.

The EMBL-EBI Industry Programme

Astellas

Kazuhisa Tsunoyama and Hiroki Shirai, Astellas Pharma, Inc.

The EMBL-EBI Industry Programme has been an important and vibrant part of EMBL-EBI since 1996, providing regular contact and interaction with key stakeholders and opinion leaders at major global commercial companies and informing them of the institute’s future directions.

The EMBL-EBI Industry Programme is a subscription-based programme for global companies that make significant use of the data and resources provided by EMBL-EBI as a core part of their R&D. Member companies represent most of the top 20 pharmaceutical companies as well as several major agri-food, nutrition and healthcare companies.

The programme is unique, providing regular quarterly strategy meetings, expert-level workshops on topics prioritised by the members, webinars and other activities. It also serves as an interface between industry-focussed initiatives at EMBL-EBI and organisations such as the Innovative Medicines Initiative (IMI), the Pistoia Alliance, the Clinical Data Interchange Standards Consortium (CDISC) and others.

Industry Programme Members

Pharmaceutical

Abbvie logo 2016Astellas - EMBL-EBI Industry Programme memberAstex - EMBL-EBI Industry Programme memberAstraZeneca - EMBL-EBI Industry Programme memberBayer - EMBL-EBI Industry Programme memberBiogen - EMBL-EBI Industry Programme memberBoehringer Ingelheim - EMBL-EBI Industry Programme memberBristol-Myers-Squibb - EMBL-EBI Industry Programme memberGalderma - a member of the EMBL-EBI Industry ProgrammeGSK - EMBL-EBI Industry Programme memberJanssen - EMBL-EBI Industry Programme memberLilly - EMBL-EBI Industry Programme memberMerck - EMBL-EBI Industry Programme memberMedImmune - EMBL-EBI Industry Programme memberMSD company logoNovartis - EMBL-EBI Industry Programme memberNovo Nordisk - EMBL-EBI Industry Programme memberPfizer - EMBL-EBI Industry Programme memberRoche - EMBL-EBI Industry Programme memberSanofi - EMBL-EBI Industry Programme memberTakeda: A member of the EMBL-EBI Industry ProgrammeUCB - EMBL-EBI Industry Programme member

 

Agri-food and consumer goods

Bayer CropScience - EMBL-EBI Industry Programme memberNestle IHS logo 2016Syngenta - EMBL-EBI Industry Programme memberUniLever - EMBL-EBI Industry Programme member

Engaging with industry

In addition to the Industry Programme, EMBL-EBI addresses the needs of industry in a number of ways. Through our participation in the Innovative Medicines Initiative (IMI), we lead projects ranging from drug safety databases to semantic enrichment of scientific literature. We support small and medium-sized enterprise (SMEs) by providing essential data infrastructure and services, enable bioinformatics spin-outs from EMBL and facilitate key pre-competitive and translational projects with our industry partners.

We welcome industry to engage with ELIXIR, the emerging pan-European infrastructure for biological information. Working together, we can empower research and the translation of discoveries into advances in medicine, health, and agriculture for the benefit of society.

Small and medium-sized enterprise

We support SMEs primarily by providing free data, tools and infrastructure. We also organise networking events in collaboration with organisations such as OneNucleus, the UK Trade and Investment agency (UKTI), the InnovateUK Bioinformatics knowledge-transfer network and the ELIXIR SME and Innovation Forum.

 

Value and impact report: highlight